Compare Arista Networks Inc (ANET) vs Moderna, Inc. (MRNA) Price & Performance

Arista Networks (ANET) trades at $208.47, up 8.85% in the last session, reflecting strong momentum amid robust AI-driven demand. The stock shows bullish technical signals with consistent earnings beats and accelerating revenue growth, reaching $9.01B in 2025. Analyst consensus remains overwhelmingly positive with a $252.25 price target, though valuation multiples appear elevated at P/E 62.61 and P/S 23.94. Recent news highlights insider selling but maintains confidence in the company's AI networking leadership.

Outlook remains favorable given hyperscaler capex expansion and Ethernet market share gains, but risks include premium valuation compression and competitive pressures. The stock offers growth exposure to AI infrastructure with solid execution, though investors should weigh high expectations against potential volatility.

Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.

The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.